285 related articles for article (PubMed ID: 30714167)
1. Plasma Epstein-Barr virus DNA as an archetypal circulating tumour DNA marker.
Lam WKJ; Chan KCA; Lo YMD
J Pathol; 2019 Apr; 247(5):641-649. PubMed ID: 30714167
[TBL] [Abstract][Full Text] [Related]
2. Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma.
Lam WKJ; Jiang P; Chan KCA; Cheng SH; Zhang H; Peng W; Tse OYO; Tong YK; Gai W; Zee BCY; Ma BBY; Hui EP; Chan ATC; Woo JKS; Chiu RWK; Lo YMD
Proc Natl Acad Sci U S A; 2018 May; 115(22):E5115-E5124. PubMed ID: 29760067
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma.
Fung SY; Lam JW; Chan KC
Chin Clin Oncol; 2016 Apr; 5(2):18. PubMed ID: 27121878
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.
Ji MF; Huang QH; Yu X; Liu Z; Li X; Zhang LF; Wang P; Xie SH; Rao HL; Fang F; Guo X; Liu Q; Hong MH; Ye W; Zeng YX; Cao SM
Cancer; 2014 May; 120(9):1353-60. PubMed ID: 24477877
[TBL] [Abstract][Full Text] [Related]
5. Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes.
Nicholls JM; Lee VH; Chan SK; Tsang KC; Choi CW; Kwong DL; Lam KO; Chan SY; Tong CC; So TH; Leung TW; Luk MY; Khong PL; Lee AW
Br J Cancer; 2019 Oct; 121(8):690-698. PubMed ID: 31527689
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA.
Stevens SJ; Verkuijlen SA; Hariwiyanto B; Harijadi ; Paramita DK; Fachiroh J; Adham M; Tan IB; Haryana SM; Middeldorp JM
Int J Cancer; 2006 Aug; 119(3):608-14. PubMed ID: 16572427
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of Epstein-Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma.
Tan R; Phua SKA; Soong YL; Oon LLE; Chan KS; Lucky SS; Mong J; Tan MH; Lim CM
Cancer Commun (Lond); 2020 Nov; 40(11):564-585. PubMed ID: 32989921
[TBL] [Abstract][Full Text] [Related]
8. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
9. Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein-Barr virus DNA in post-treatment plasma.
Chan DCT; Lam WKJ; Hui EP; Ma BBY; Chan CML; Lee VCT; Cheng SH; Gai W; Jiang P; Wong KCW; Mo F; Zee B; King AD; Le QT; Chan ATC; Chan KCA; Lo YMD
Ann Oncol; 2022 Aug; 33(8):794-803. PubMed ID: 35491007
[TBL] [Abstract][Full Text] [Related]
10. Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program.
Chan KC; Hung EC; Woo JK; Chan PK; Leung SF; Lai FP; Cheng AS; Yeung SW; Chan YW; Tsui TK; Kwok JS; King AD; Chan AT; van Hasselt AC; Lo YM
Cancer; 2013 May; 119(10):1838-44. PubMed ID: 23436393
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.
Li WF; Zhang Y; Huang XB; Du XJ; Tang LL; Chen L; Peng H; Guo R; Sun Y; Ma J
Chin J Cancer; 2017 Nov; 36(1):87. PubMed ID: 29116021
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin.
Ramayanti O; Juwana H; Verkuijlen SA; Adham M; Pegtel MD; Greijer AE; Middeldorp JM
Int J Cancer; 2017 Jan; 140(1):149-162. PubMed ID: 27600027
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma.
Shao JY; Zhang Y; Li YH; Gao HY; Feng HX; Wu QL; Cui NJ; Cheng G; Hu B; Hu LF; Ernberg I; Zeng YX
Anticancer Res; 2004; 24(6):4059-66. PubMed ID: 15736452
[TBL] [Abstract][Full Text] [Related]
14. Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus-associated diseases.
Lam WKJ; Jiang P; Chan KCA; Peng W; Shang H; Heung MMS; Cheng SH; Zhang H; Tse OYO; Raghupathy R; Ma BBY; Hui EP; Chan ATC; Woo JKS; Chiu RWK; Lo YMD
Nat Commun; 2019 Jul; 10(1):3256. PubMed ID: 31332191
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of plasma EBV DNA as a biomarker for nasopharyngeal carcinoma in non-endemic areas: A multicenter study in southwestern China.
He Q; Zhou Y; Zhou J; Zhao D; Li L; Li X; Huang Y; Wang Q; Zou H; Zhang K; Li Y; Wang Z; Deng Y; Meng F; Ying B; Yang M; Wang D
Clin Chim Acta; 2023 Feb; 541():117244. PubMed ID: 36746264
[TBL] [Abstract][Full Text] [Related]
16. Clinical applications of plasma Epstein-Barr virus DNA analysis and protocols for the quantitative analysis of the size of circulating Epstein-Barr virus DNA.
Chan KC; Lo YM
Methods Mol Biol; 2006; 336():111-21. PubMed ID: 16916257
[TBL] [Abstract][Full Text] [Related]
17. Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area.
Alfieri S; Iacovelli NA; Marceglia S; Lasorsa I; Resteghini C; Taverna F; Mazzocchi A; Orlandi E; Guzzo M; Bianchi R; Fanti D; Pala L; Racca S; Dvir R; Quattrone P; Gloghini A; Volpi CC; Granata R; Bergamini C; Locati L; Licitra L; Bossi P
Oncotarget; 2017 Jul; 8(29):47780-47789. PubMed ID: 28562354
[TBL] [Abstract][Full Text] [Related]
18. Circulating Epstein-Barr virus microRNAs miR-BART7 and miR-BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment.
Zhang G; Zong J; Lin S; Verhoeven RJ; Tong S; Chen Y; Ji M; Cheng W; Tsao SW; Lung M; Pan J; Chen H
Int J Cancer; 2015 Mar; 136(5):E301-12. PubMed ID: 25213622
[TBL] [Abstract][Full Text] [Related]
19. Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma.
Chan KC
Chin J Cancer; 2014 Dec; 33(12):598-603. PubMed ID: 25418194
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus biomarkers for nasopharyngeal carcinoma in non-endemic regions.
Gurtsevitch VE; Senyuta NB; Ignatova AV; Lomaya MV; Kondratova VN; Pavlovskaya AI; Dushenkina TE; Maximovich DM; Smirnova KV; Mudunov AM; Lichtenstein AV
J Gen Virol; 2017 Aug; 98(8):2118-2127. PubMed ID: 28786806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
